The combination treatment of atizumab (anti-PD-L1) and bevacizumab (anti-VEGF) significantly improved the survival rate of patients in the IMbrave150 trial, becoming a new standard of first-line treatment for liver cancer (9). The gene discussed is VEGFA; the disease is liver cancer.